Predict response across alternative cancer therapies
One patient. Multiple possible outcomes.
Using multimodal patient data to model how the same patient may respond to different treatments.
STARTING WITH BREAST CANCER
Many authorised therapies.
Only lung cancer has more authorised active substances, but in lung cancer, the treatment decision depends more on mutations.
31
Active substances authorised in the EU with breast cancer as an indication
Source: European Medicines Agency, medicines database, as of 01.11.2026. Aileen Health count.
Cancer4D: Beyond standard of care
what WE can do
Why not an LLM? Precision medicine requires reproducible predictions - with an LLM the same prompt gives different results.
Generative AI is described as a seismic shift
Fully embedded into existing research infrastructure, for curated data and feedback from 300 healthcare providers
We trained Cancer4D with breast and brain images, and are extending our capabilities to lung and prostate
OUR TEAM
Scientific, technical, and business
Our team has decades of experience in AI and working with healthcare systems
Our next stops
Meet us in person when we are on the road
We’d love to meet you in person!
05 Nov 2026 – 05 Nov 2026
Linz, Austria
JKU Entrepreneurship Center Opening
06 Nov 2026 – 06 Nov 2026
Amsterdam, Netherlands
EMA SME Info day
17 Nov 2026 – 18 Nov 2026
Brussels, Belgium
WKÖ Global Insights: Executive Mission Brussels
Get notified when we have more news
Subscribe to our updates and follow our research progress.
